First-in-human randomized controlled trial of an oral, replicating adenovirus 26 vector vaccine for HIV-1

Safety evaluation of adenovirus type 4 and type 7 vaccine live, oral in military recruits

(2016) Azhar Choudhry et al.   VACCINE

Attenuation of Replication-Competent Adenovirus Serotype 26 Vaccines by Vectorization

(2015) Lori F. Maxfield et al.   Clinical and Vaccine Immunology

Induction of HIV-1–Specific Mucosal Immune Responses Following Intramuscular Recombinant Adenovirus Serotype 26 HIV-1 Vaccination of Humans

(2014) Lindsey R. Baden et al.   JOURNAL OF INFECTIOUS DISEASES

Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study

(2013) Marc Gurwith et al.   LANCET INFECTIOUS DISEASES

A phase 3, randomized, double-blind, placebo-controlled study of the safety and efficacy of the live, oral adenovirus type 4 and type 7 vaccine, in U.S. military recruits

(2013) Robert A. Kuschner et al.   VACCINE

Development of replication-competent viral vectors for HIV vaccine delivery

(2013) Christopher L. Parks et al.   Current Opinion in HIV and AIDS

First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Adenovirus Serotype 26 HIV-1 Env Vaccine (IPCAVD 001)

(2012) Lindsey R. Baden et al.   JOURNAL OF INFECTIOUS DISEASES

Characterization of Humoral and Cellular Immune Responses Elicited by a Recombinant Adenovirus Serotype 26 HIV-1 Env Vaccine in Healthy Adults (IPCAVD 001)

(2012) Dan H. Barouch et al.   JOURNAL OF INFECTIOUS DISEASES

Adenovirus Serotype 26 Utilizes CD46 as a Primary Cellular Receptor and Only Transiently Activates T Lymphocytes following Vaccination of Rhesus Monkeys

(2012) H. Li et al.   JOURNAL OF VIROLOGY

A double-blind, placebo-controlled study of the safety and immunogenicity of live, oral type 4 and type 7 adenovirus vaccines in adults

(2008) Arthur Lyons et al.   VACCINE